Shao Chang-Le, Cui Guo-Hong, Guo Hai-Dong
Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Department of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Pharmacol. 2022 Jan 26;13:816347. doi: 10.3389/fphar.2022.816347. eCollection 2022.
Taohong Siwu decoction (THSWD) is one of the classic prescriptions for promoting blood circulation and removing blood stasis. With the continuous in-depth excavation in basic and clinical research, it has been found that THSWD has made greater progress in the prevention and treatment of cardiovascular diseases. Mechanisms of the current studies have shown that it could prevent and treat the myocardial injury by inhibiting inflammatory reaction, antioxidant stress, inhibiting platelet aggregation, prolonging clotting time, anti-fibrosis, reducing blood lipids, anti-atherosclerosis, improving hemorheology and vascular pathological changes, regulating related signal pathways and other mechanisms to prevent and treat the myocardial injury, so as to protect cardiomyocytes and improve cardiac function. Many clinical studies have shown that THSWD is effective in the prevention and treatment of cardiovascular diseases related to myocardial injuries, such as coronary heart disease angina pectoris (CHD-AP), and myocardial infarction. In clinical practice, it is often used by adding and subtracting prescriptions, the combination of compound prescriptions and combinations of chemicals and so on. However, there are some limitations and uncertainties in both basic and clinical research of prescriptions. According to the current research, although the molecular biological mechanism of various active ingredients needs to be further clarified, and the composition and dose of the drug have not been standardized and quantified, this study still has exploration for scientific research and clinical practice. Therefore, this review mainly discusses the basic mechanisms and clinical applications of THSWD in the prevention and treatment of the myocardial injury caused by CHD-AP and myocardial infarction. The authors hope to provide valuable ideas and references for researchers and clinicians.
桃红四物汤是活血化瘀的经典方剂之一。随着基础与临床研究的不断深入挖掘,发现桃红四物汤在心血管疾病的防治方面取得了较大进展。目前的研究机制表明,它可通过抑制炎症反应、抗氧化应激、抑制血小板聚集、延长凝血时间、抗纤维化、降低血脂、抗动脉粥样硬化、改善血液流变学及血管病理改变、调节相关信号通路等机制来防治心肌损伤,从而保护心肌细胞并改善心脏功能。多项临床研究表明,桃红四物汤在防治与心肌损伤相关的心脑血管疾病方面有效,如冠心病心绞痛(CHD - AP)和心肌梗死。在临床实践中,常采用方剂加减、复方配伍以及与化学药物联合等方式使用。然而,方剂的基础和临床研究均存在一些局限性和不确定性。根据目前的研究,尽管各种活性成分的分子生物学机制有待进一步阐明且药物的组成和剂量尚未标准化和量化,但本研究仍对科研和临床实践具有探索意义。因此,本综述主要探讨桃红四物汤在防治CHD - AP和心肌梗死所致心肌损伤方面的基础机制及临床应用。作者希望为研究人员和临床医生提供有价值的思路和参考。